Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Canadian Cancer Trials Group HE.1: A phase III study of palliative radiotherapy for symptomatic hepatocellular carcinoma and liver metastases.
Authors
Laura A. Dawson
Princess Margaret Cancer Centre, Toronto, ON, Canada;
Laura A. Dawson , Alysa M. Fairchild , Kristopher Dennis , Aamer Mahmud , Teri Lynn Stuckless , Francois Vincent , David Roberge , Matthew Follwell , Raimond K.W. Wong , Derek J. Jonker , Jennifer J. Knox , Camilla Zimmermann , Philip Wong , Tom Purdie , Jolie Ringash , Aisling S Barry , Marc Gaudet , Dongsheng Tu , Rebecca KS Wong , Christopher J. O'Callaghan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
NCT02511522
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr LBA492)
DOI
10.1200/JCO.2023.41.4_suppl.LBA492
Abstract #
LBA492
Poster Bd #
A1
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.
First Author: Ronac Mamtani
Poster
2023 ASCO Annual Meeting
A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatment.
First Author: Kirin Saint
Poster
2022 ASCO Annual Meeting
Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
First Author: Shukui Qin
Poster
2022 ASCO Annual Meeting
A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatment.
First Author: Katherine Han